Related Experiment Videos

[Effect of corinfar on hemodynamics in ischemic heart disease]

Terapevticheskii Arkhiv
|January 1, 1986
PubMed

Insights

Corinfar, administered sublingually, significantly lowers blood pressure and peripheral resistance in coronary heart disease (CHD) patients within one hour. This medication also increases heart rate and cardiac output, improving cardiovascular function.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Coronary heart disease (CHD) poses significant cardiovascular risks.
  • Effective management of hypertension and cardiac function in CHD patients is crucial.

Purpose of the Study:

  • To evaluate the efficacy of sublingual Corinfar in managing hemodynamic parameters in CHD patients.
  • To assess the impact of Corinfar on blood pressure, cardiac output, and vascular resistance.

Main Methods:

  • A double-blind, placebo-controlled study was conducted.
  • Corinfar was administered sublingually at doses of 10-30 mg.
  • Hemodynamic parameters including arterial pressure, peripheral resistance, heart rate, and cardiac volumes were measured.

Main Results:

  • Sublingual Corinfar significantly decreased systolic and diastolic arterial pressure within one hour.
  • The medication reduced general peripheral resistance while increasing heart rate, stroke volume, and minute volume.
  • Increased systolic discharge correlated with reduced arteriolar tension.

Conclusions:

  • Sublingual Corinfar demonstrates potent antihypertensive and cardioprotective effects in CHD patients.
  • The drug effectively modulates key hemodynamic parameters, suggesting a therapeutic role in managing CHD complications.

Related Concept Videos